default author photo

Junji Tsurutani

affiliation not provided to SSRN

  • affiliation not provided to SSRN

SCHOLARLY PAPERS

1

DOWNLOADS

46

TOTAL CITATIONS

0

Scholarly Papers (1)

Actions:
Email selected abstracts
1.

Safety and Efficacy of Nivolumab Plus Bevacizumab, Paclitaxel for HER2-Negative Metastatic Breast Cancer: Primary Result and Biomarker Data of a Phase 2 Trial

Number of pages: 51 Posted: 03 Mar 2022
Yukinori Ozaki, Junji Tsurutani, Toru Mukohara, Tsutomu Iwasa, Masato Takahashi, Yuko Tanabe, Hidetaka Kawabata, Norikazu Masuda, Manabu Futamura, Hironobu Minami, Koji Matsumoto, Kenichi Yoshimura, Shigehisa Kitano and Toshimi Takano
Toranomon Hospital - Department of Medical Oncology, affiliation not provided to SSRN, National Cancer Center Hospital East - Department of Breast and Medical Oncology, Kindai University - Department of Medical Oncology, Hokkaido University - Hokkaido University Hospital, Toranomon Hospital - Department of Medical Oncology, Toranomon Hospital - Department of Breast and Endocrine Surgery, Nagoya University - Graduate School of Medicine, Gifu University - Department of Surgical Oncology, Kobe University - Medical Oncology/Hematology, affiliation not provided to SSRN, Hiroshima University Hospital - Center for Integrated Medical Research, National Cancer Center Hospital - Department of Experimental Therapeutics and Toranomon Hospital - Department of Medical Oncology
Downloads 46 (1,109,210)

Abstract:

Loading...

Nivolumab, Bevacizumab, immunotherapy, VEGF, Metastatic breast cancer